After seeing a 100 percent response rate in Phase I, Indian health authorities said the firm can test ribrecabtagene autoleucel in Phase II of the SWASTH trial.
The London-based firm said it will use the funds to advance its gene therapy pipeline, including its lead program in IgA nephropathy.
The firm is focusing its resources on developing its lead candidate, the EGFR inhibitor BDTX-1535, which is undergoing testing in EGFR-mutated NSCLC.
The new consortium, dubbed Thera4Care, launched with €25.3 million in EU government funding and 29 academic and industry partners.
The partners are studying a drug designed to target EGFR exon 19 or exon 21 mutations with a co-occurring C797S mutation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback